Soleno Therapeutics: Why I'm Staying On The Sidelines [Seeking Alpha]
Soleno Therapeutics, Inc. (SLNO)
Last soleno therapeutics, inc. earnings: 5/13 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.soleno.life/investor-overview
Company Research
Source: Seeking Alpha
VYKAT's initial revenues and profitability are encouraging, but real-world persistence, tolerability, and dose reductions may constrain long-term upside. Fourth-quarter revenues are projected at $90–92 million, yet new patient starts and active patient disclosures raise questions about ongoing demand. SLNO's financial health is robust with $500 million cash and a $100 million buyback, but market efficiency suggests current valuation reflects key risks. Case_Hensler/iStock via Getty Images As is often the case in the biotechnology sector, post-approval hype can give way to commercial realities. Judging by its recent stock performance, this appears to be the case for Soleno Therapeutics, Inc. ( SLNO This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I a
Show less
Read more
Impact Snapshot
Event Time:
SLNO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLNO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLNO alerts
High impacting Soleno Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SLNO
News
- SLNO INVESTOR ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Fraud InvestigationGlobeNewswire
- Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid Disappointing VYKAT XR Starts, Discontinuations; Shares Down 26% -- Hagens BermanGlobeNewswire
- Soleno Therapeutics (NASDAQ:SLNO) was given a new $107.00 price target on by analysts at Robert W. Baird.MarketBeat
- SLNO Investors: Contact Kirby McInerney LLP About Investigation into Soleno Therapeutics, Inc.Business Wire
- Soleno Therapeutics (NASDAQ:SLNO) had its "outperform" rating reaffirmed by analysts at Wolfe Research.MarketBeat
SLNO
Earnings
- 11/4/25 - Beat
SLNO
Sec Filings
- 1/12/26 - Form 8-K
- 12/17/25 - Form 4
- 12/17/25 - Form 4
- SLNO's page on the SEC website